Market revenue in 2023 | USD 196.4 million |
Market revenue in 2030 | USD 796.3 million |
Growth rate | 22.1% (CAGR from 2023 to 2030) |
Largest segment | Adeno-associated virus (aav) |
Fastest growing segment | Adeno-associated virus (AAV) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector and plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Adeno-associated virus (aav) was the largest segment with a revenue share of 20.16% in 2023. Horizon Databook has segmented the India viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2018 to 2030.
The Growing community awareness about cell and gene therapy promotes industrial growth. The availability of licensed gene therapy products and increase in adoption of cell & gene therapy products to treat various diseases are the key factors driving market growth in India.
Furthermore, plasmid DNA serves as the basis for gene therapies as well as DNA vaccines for a variety of infectious, hereditary & acquired disorders, as well as enteric infections.
Moreover, plasmid DNA is in demand in India due to the increase in R&D efforts for improving medicines that target a disease's genomic origin, due to the rising demand for effective disease treatment therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the India viral vector and plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into India viral vector and plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account